Enantioselective Total Synthesis of (-)-Finerenone Using Asymmetric Transfer Hydrogenation

被引:12
|
作者
Lerchen, Andreas [1 ]
Gandhamsetty, Narasimhulu [1 ]
Farrar, Elliot H. E. [2 ]
Winter, Nils [1 ]
Platzek, Johannes [3 ]
Grayson, Matthew N. [2 ]
Aggarwal, Varinder K. [1 ]
机构
[1] Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England
[2] Univ Bath, Dept Chem, Bath BA2 7AY, Avon, England
[3] Bayer AG, Chem Dev, D-42096 Wuppertal, Germany
基金
英国工程与自然科学研究理事会;
关键词
enantioselective synthesis; MR antagonists; partial transfer hydrogenation; pharmaceutical molecule; CASCADE REACTION; ACID; REDUCTION; TETRAHYDROQUINOLINES; ANTAGONIST; QUINOLINES; DISCOVERY; CATALYST; RECEPTOR;
D O I
10.1002/anie.202011256
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
(-)-Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase III clinical trials for the treatment of chronic kidney disease in type 2 diabetes. It contains an unusual dihydronaphthyridine core. We report a 6-step synthesis of (-)-finerenone, which features an enantioselective partial transfer hydrogenation of a naphthyridine using a chiral phosphoric acid catalyst with a Hantzsch ester. The process is complicated by the fact that the naphthyridine exists as a mixture of two atropisomers that react at different rates and with different selectivities. The intrinsic kinetic resolution was converted into a kinetic dynamic resolution at elevated temperature, which enabled us to obtain (-)-finerenone in both high yield and high enantioselectivity. DFT calculations have revealed the origin of selectivity.
引用
收藏
页码:23107 / 23111
页数:5
相关论文
共 50 条